PDCD1 and esophageal squamous cell carcinoma: Nivolumab, an anti-PD-1 antibody, monotherapy as the second-line treatment significantly improves the survival of patients with unresectable advanced or recurrent esophageal squamous cell carcinoma (ESCC) [2,3].